Delphi advisor to LIDDS AB (publ) in connection with a directed issue

Delphi has advised LIDDS AB (publ) in connection with a directed issue to a number of Swedish and international investors. The directed issue has been resolved by the Board of Directors of LIDDS pursuant to the authorization granted by the Annual General Meeting on May 17, 2021. LIDDS will be provided with an amount of approximately SEK 45 million before issue costs.

LIDDS is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and provide a controlled and sustained release of active drug substances for up to six months. LIDDS shares are listed on Nasdaq First North Growth Market.

Delphi’s team consisted of Mats Dahlberg and Pekka Frölander.